Autolus Therapeutics
AUTL
71 hedge funds and large institutions have $258M invested in Autolus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 25 reducing their positions, and 8 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more capital inflows, than outflows
Capital inflows: $21.9M | Capital outflows: $15.5M
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 69 → 71 (+2)
0.57% more ownership
Funds ownership: 63.21% → 63.78% (+0.57%)
44% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
+$14.8M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$3.88M |
| 3 |
Affinity Asset Advisors
New York
|
+$1.15M |
| 4 |
Schonfeld Strategic Advisors
New York
|
+$830K |
| 5 |
Renaissance Technologies
New York
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$10.2M |
| 2 |
Odey Asset Management
London, United Kingdom,
United Kingdom
|
-$1.57M |
| 3 |
Armistice Capital
New York
|
-$1.04M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$442K |
| 5 |
EdenTree Asset Management
London,
United Kingdom
|
-$430K |
AUTL Hedge Fund Activity: Q3 2023 in Review
71 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2023, worth a combined $258M — down 0.85% from $260M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AUTL positions and 8 closed out — a net gain of 2 holders — while 14 added to existing stakes and 25 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $14.8M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $10.2M sold.
- 71 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2023, up from 69 in Q2 2023.
- Funds reported $258M of Autolus Therapeutics stock for Q3 2023, down 0.85% quarter-over-quarter.
- 10 funds opened new Autolus Therapeutics positions in Q3 2023 and 8 closed out, a net change of +2 holders.
- The largest Autolus Therapeutics buyer in Q3 2023 was Paradigm Biocapital Advisors, an estimated $14.8M added.
- The largest Autolus Therapeutics seller in Q3 2023 was Nantahala Capital Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2023.